SCHEMBL347435

SCHEMBL347435

CC(=O)Oc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1C[C@@H](O)[C@@H]2OC(=O)c1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 6/20 0.66
LMNA P02545 5/20 0.66
SMN1; SMN2 Q16637 3/20 0.66
ATM Q13315 3/20 0.66
KMT2A Q03164 3/20 0.66
ADORA3 P0DMS8 2/20 0.66
NR3C1 P04150 2/20 0.66
SHBG P04278 2/20 0.66
SLC6A4 P31645 2/20 0.66
FYN P06241 1/20 0.66
ADRA2C P18825 1/20 0.66
SLC6A2 P23975 1/20 0.66
HTR2B P41595 1/20 0.66
HTT P42858 1/20 0.66
PGR P06401 2/20 0.63
AR P10275 2/20 0.63
SLC6A3 Q01959 2/20 0.63
CHRM1 P11229 1/20 0.63
TBXA2R P21731 1/20 0.63
ADRA1A P35348 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10360627 0.95 ESR1 (0.73) ESR1LMNASMN1; SMN2ATMKMT2A
SCHEMBL8208515 0.93 ESR1 (0.71) ESR1LMNASMN1; SMN2ATMKMT2A
SCHEMBL10361010 0.90 SMN1; SMN2 (0.71) ESR1LMNASMN1; SMN2ATMKMT2A
SCHEMBL347436 0.89 ESR1 (0.67) ESR1LMNASMN1; SMN2ATMKMT2A
SCHEMBL8177993 0.89 ESR1 (0.65) ESR1LMNASMN1; SMN2ATMKMT2A
SCHEMBL8619796 0.87 LMNA (0.69) ESR1LMNASMN1; SMN2ATMKMT2A
SCHEMBL8177995 0.86 ESR1 (0.78) ESR1LMNASMN1; SMN2ATMKMT2A
SCHEMBL14360870 0.86 ESR1 (0.78) ESR1LMNASMN1; SMN2ATMKMT2A
SCHEMBL3299315 0.85 MAPT (0.81) ESR1LMNASMN1; SMN2ATMKMT2A
SCHEMBL5711620 0.85 LMNA (0.68) ESR1LMNASMN1; SMN2ATMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014080-A1 LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF VAN BOGAERT GINA (BE) 2026-01-15 US disclosed
WO-2023223235-A1 LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF PURNA PHARMACEUTICALS NV (BE) 2023-11-23 WO disclosed
EP-1719768-B1 NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS ASAHI KASEI PHARMA CORP (JP) 2012-04-25 EP disclosed
US-20120015925-A1 NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS ASAHI KASEI PHARMA CORPORATION (JP) 2012-01-19 US disclosed
US-7973030-B2 Benzothiazepine and benzothiepine compounds ASAHI KASEI PHARMA CORPORATION (JP) 2011-07-05 US disclosed
US-20100291242-A1 ANTAGONIST AGAINST TOLERANCE TO ANTICANCER DRUGS YOSHIKAZU SUGIMOTO (JP) 2010-11-18 US disclosed
US-20080249036-A1 Antagonist Against Tolerance to Anticancer Drugs YOSHIKAZU SUGIMOTO (JP) 2008-10-09 US disclosed
US-20070190041-A1 Novel benzothiazepine and bensothiepine compounds ASHAI KASEI PHARAMA CORPORATION (JP) 2007-08-16 US disclosed
US-20070166362-A1 Transdermal and transmucosal preparations KABUSHIKI KAISHA SANGI (JP) 2007-07-19 US disclosed
EP-1797900-A1 PREPARATION FOR PERCUTANEOUS/PERMUCOSAL ABSORPTION KABUSHIKI KAISHA SANGI (JP) 2007-06-20 EP disclosed
EP-1785139-A1 ANTAGONIST AGAINST TOLERANCE TO ANTICANCER DRUGS JAPANESE FOUNDATION FOR CANCER RESEARCH (JP) 2007-05-16 EP disclosed
EP-1719768-A1 NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS Asahi Kasei Pharma Corporation (JP) 2006-11-08 EP disclosed
US-6444420-B2 NERVOUS SYSTEM DISORDERS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2002-09-03 US disclosed
US-20010016325-A1 Activation of novel estrogen receptor supports and neuronal viability and function BOARD OF TRUSTEE OF THE LELAND STANFORD JUNIOR UNIVERSITY, THE 2001-08-23 US disclosed
US-6265147-B1 DETECTING MODULATORS OF BRAIN ACTIVITY; MIX MODULATOR WITH RECEPTORS AND DETECT ACTIVATION OF RECEPTORS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2001-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014080-A1 LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF NR5A1, SHBG, GNRHR ESR1 188/4885LMNA 796/4885SMN1; SMN2 2999/4885
US-20010016325-A1 Activation of novel estrogen receptor supports and neuronal viability and function ESR1, GPER1, ESR2 ESR1 1/4885LMNA 3505/4885SMN1; SMN2 166/4885
US-20120015925-A1 NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS SLC10A1, SREBF1, SPTLC1 ESR1 1904/4885LMNA 1909/4885SMN1; SMN2 4162/4885
US-20070190041-A1 Novel benzothiazepine and bensothiepine compounds SLC10A1, GOT1, CES1 ESR1 2170/4885LMNA 2785/4885SMN1; SMN2 4351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.